No­var­tis-backed In­fla­zome rais­es $46M for their clin­i­cal chal­lenge to prove NL­RP3 is a great an­ti-in­flam­ma­to­ry tar­get

The big CAN­TOS study may not have pro­duced the block­buster ap­proval that No­var­tis had been promis­ing in car­dio, but its suc­cess in the IL-1 be­ta path­way has helped in­spire a slate of star­tups that are mov­ing up­stream to what’s be­come a hot field in NL­RP3 in­hi­bi­tion.

To­day’s sto­ry cen­ters on In­fla­zome, which de­scribes it­self as one of the pi­o­neers in NL­RP3. The biotech has raised $46 mil­lion for its Se­ries B round to shift out of pre­clin­i­cal work and head straight in­to the clin­ic next year, with plans to tee up a safe­ty study fol­lowed by a for­ay in­to an or­phan CNS con­di­tion.

Based in Dublin and Cam­bridge, UK, where its re­search is cen­tered, the biotech al­so has an of­fice in Aus­tralia to al­low for a quick shift to hu­man tri­als, where the gov­ern­ment of­fers a hefty 43% tax cred­it for the drug tri­als un­der­tak­en Down Un­der.

Luke O’Neill

Pfiz­er, As­traZeneca, No­var­tis and oth­ers may have failed at their ear­ly at­tempts in this are­na, says CEO Matthew Coop­er, but they have all helped pave the way for In­fla­zome. Coop­er co-found­ed the com­pa­ny with Trin­i­ty Col­lege’s Luke O’Neill. They now have a dozen staffers, with plans to beef up the team now that the B round has ar­rived.

The biotech’s ear­ly work has in­volved hun­dreds of com­pounds and 29 patents cen­tered around NL­RP3, an in­flam­ma­zome that ap­pears to play a key role in push­ing in­flam­ma­tion in a long ros­ter of ail­ments big and small.

Their goal has been to iden­ti­fy the best drug can­di­date de­pend­ing on the tar­get, which starts with cry­opy­rin-as­so­ci­at­ed pe­ri­od­ic syn­drome, an or­phan in­di­ca­tion in­volv­ing hy­per-in­flam­ma­tion that can lead to men­tal re­tar­da­tion. That gives them a chance to pro­vide a proof-of-con­cept dis­play of the tech with a small study be­fore they branch out in­to big­ger dis­eases.

The biotech doesn’t go out of its way to at­tract at­ten­tion. “We’re very Eu­ro­pean in that way,” says Coop­er, a pro­fes­sor at the Uni­ver­si­ty of Queens­land who I queried af­ter the re­lease hit the wire.

At the same time, he’s clear­ly pumped and be­lieves that In­fla­zome is on a great jour­ney, start­ing with CNS and the pos­si­bil­i­ty of go­ing in­to some tough con­di­tions like Parkin­son’s and Alzheimer’s, where tamp­ing down on longterm in­flam­ma­tion could pay sol­id ben­e­fits over time.

That will re­quire com­pounds that can get in­to the brain to do their job. But out­side the brain there are plen­ty of ad­di­tion­al tar­gets, run­ning a gamut rang­ing from gout to arthri­tis to car­dio.

Like his biotech ri­vals — a group that in­cludes NodThera and IFM — Coop­er is pur­su­ing the be­lief that rather that tack­ling the en­tire IL-1 be­ta path­way, it’s pos­si­ble to much more safe­ly sin­gle out the “lone wolf” that they be­lieve is the prime sus­pect for the laun­dry list of con­di­tions it may trig­ger.

In­ter­est­ing­ly, there’s al­so been ear­ly work done to link the ke­to­genic di­et to hit­ting NL­RP3, which may ex­plain why the ul­tra low carb di­et could work in a range of cas­es for child­hood epilep­sy, as prac­ticed at Johns Hop­kins for decades. Coop­er, though, says it’s go­ing to take some­thing with re­al ther­a­peu­tic strength to have an im­pact on the dis­eases they’re af­ter, and ke­to may not qual­i­fy on that lev­el.

For­bion led the round, with Lon­gi­tude Cap­i­tal and found­ing in­vestors No­var­tis Ven­ture Fund and Foun­tain Health­care Part­ners al­so par­tic­i­pat­ing.

Im­age: Matthew Coop­er. UNI­VER­SI­TY OF QUEENS­LAND

Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety on display right up to the last minute on Twitter can now end. But new, pressing questions will immediately surface now that the OK has come through.

On Friday afternoon, the FDA stamped its landmark approval on the industrial strength fish oil for reducing cardio risks for a large and well defined population of patients. The approval doesn’t give Amarin everything it wants in expanding its use, losing out on the primary prevention group, but it goes a long way to doing what the company needed to make a major splash. The approval was cited for patients with “elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Getty Images

Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

Sarepta has a friend in the FDA after all. Four months after the agency determined that it would be wrong to give Sarepta an accelerated approval for their Duchenne MD drug golodirsen, regulators have executed a stunning about face and offered the biotech a quick green light in any case.

It was the agency that first put out the news late Thursday, announcing that Duchenne MD patients with a mutation amenable to exon 53 skipping will now have their first targeted treatment: Vyondys 53, or golodirsen. Having secured the OK via a dispute resolution mechanism, the biotech said the new drug has been priced on par with their only other marketed drug, Exondys 51 — which for an average patient costs about $300,000 per year, but since pricing is based on weight, that sticker price can even cross $1 million.

Sarepta shares $SRPT surged 23% after-market to $124.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Paul Biondi (File photo)

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

Paul Biondi was never afraid to bet big during his stint as business development chief at Bristol-Myers Squibb. And while the gambles didn’t all pay out, by any means, his roster of pacts illustrates the broad ambitions the pharma giant has had over the last 5 years — capped by the $74 billion Celgene buyout.

On Thursday, we learned that Biondi had exited the company. And Chris Dokomajilar at DealForma came up with the complete breakdown on every buyout, licensing pact and product purchase Bristol-Myers forged during his tenure in charge of the BD team at one of the busiest companies in biopharma.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Arie Belldegrun (Photo: Jeff Rumans for Endpoints News)

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

A Kite deal that’s already become a burden on Gilead’s back just got heavier as a California jury has ruled Gilead must pay Bristol-Myers Squibb and Sloan Kettering $585 million plus a 27.6% royalty for patent infringement committed by its subsidiary. The ruling is almost certain to be appealed.

Kite Pharma — founded by Arie Belldegrun, now focused on a next-gen CAR-T company — has been facing a lawsuit since the day its first CAR–T therapy won approval in October, 2017. Juno Therapeutics and Sloan Kettering filed a complaint saying Kite had copied its technology. Gilead acquired Kite in June of that year for $11.9 billion.  Juno was acquired the following year by Celgene for $9 billion, before Celgene was acquired by Bristol-Myers Squibb in 2019.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

FDA ex­pert pan­el unan­i­mous­ly rec­om­mends ap­proval for Hori­zon Ther­a­peu­tics eye drug

An FDA advisory committee noted with concern a small safety database but unanimously endorsed a Horizon Therapeutics drug for a rare eye autoimmune disease that can blind patients: teprotumumab for thyroid eye disease (TED).

“It was a pretty easy vote,” said Erica Brittain, an NIH biostatistician and one of the 12 panelists on FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee.

This image shows a lab technician measuring the zone of inhibition during an antibiotic sensitivity test, 1972. The zone of inhibition is measured and compared to a standard in order to determine if an antibiotic is effective in treating the bacterial infection. (Gilda Jones/CDC via Getty Images)

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

Timing is Everything
When we launched Octagon Therapeutics in late 2017, I was convinced that the time was right for a new antibiotic discovery venture. The company was founded on impressive academic pedigree and the management team had known each other for years. Our first program was based on a compelling approach to targeting central metabolism in the most dangerous bacterial pathogens. We had already shown a high level of efficacy in animal infection models and knew our drug was safe in humans.

Shehnaaz Suli­man dives back in­to Alzheimer's at Alec­tor; Pyx­is re­cruits Spring­Works founder Lara Sul­li­van as CEO

Amid Shehnaaz Suliman’s lengthy resume it could be easy to miss her stint leading early-stage Alzheimer’s R&D at Genentech, where she oversaw a program for the ill-fated crenezumab and initiated one of the first prevention studies around the devastating neurodegenerative disease. But it is this experience that she — after thinking long and hard about her next career move over the past months — will be leaning heavily on as the first president and COO of Alector.

PhII fail­ure in rare neu­rode­gen­er­a­tive dis­ease? No mat­ter, Bio­gen will mo­tor on in Alzheimer's

Biogen’s fierce focus on disorders of the brain has hit another roadblock.

On Friday, the US drugmaker — which recently resurrected its amyloid-targeting Alzheimer’s drug, aducanumab — said its anti-tau drug, gosuranemab, failed a mid-stage study in patients with progressive supranuclear palsy (PSP), a rare brain disorder that results from deterioration of brain cells that control movement and thought.